Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros




Base de datos
Intervalo de año de publicación
1.
Ann Transl Med ; 10(18): 1017, 2022 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-36267740

RESUMEN

Background: Type 2 diabetes (T2D) is a prevalent chronic disease with elusive. Combining transcriptome and single-cell sequencing data to explore biomarkers of T2D could provide new insights into the in-depth understanding of the molecular mechanisms and diagnosis of T2D. Methods: The GSE41762 dataset including RNA-seq data for healthy and T2D patients, was obtained from the Gene Expression Omnibus (GEO) database. The potential functions of the differentially expressed genes (DEGs) were revealed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Moreover, biomarkers were screened out by the Least Absolute Shrinkage and Selection Operator (LASSO) algorithm and receiver operating characteristic (ROC) analysis. Furthermore, single-cell RNA (sc-RNA)-seq data in the "E-MTAB-5061" dataset was downloaded from the ArrayExpress (European Bioinformatics Institute, EBI) database. Principal components analysis (PCA) and t-distributed stochastic neighbor embedding (tSNE) were used for dimensionality reduction analysis and cell clustering. The FindAllMarkers function was used annotate different cell clusters, and key cell clusters were screened by the expression levels of the biomarkers. Finally, the transcription factors (TFs) of the biomarkers were recognized. Results: A total of 111 DEGs were screened in the GSE41762 dataset, which were mainly related to hormone secretion, specialized postsynaptic membrane, pancreatic secretion, JAK-STAT signaling pathway, and Ras signaling pathway. In addition, SLC2A2, SERPINF1, RASGRP1, and CHL1 were screened out as biomarkers of T2D, which possessed potential diagnostic value as AUC value greater than 0.8. A total of 1,515 T2D group cells and 1,817 healthy cohort cells were screened as core cells in the "E-MTAB-5061" dataset. Following tSNE dimensionality reduction cluster analysis, the core cells were divided into 13 cell clusters. According to the marker genes, the 13 cell clusters were annotated into six types of cells. Notably, SERPINF1 was highly expressed in fibroblasts and might be regulated by NR2F2 (nuclear receptor subfamily2, group F, and member 2). Conclusions: This study identified four biomarkers (SLC2A2, SERPINF1, RASGRP1, and CHL1) for T2D, which provided new markers for the clinical diagnosis of T2D. Among them, SERPINF1 might be regulated by NR2F2, which provides valuable insight into the pathogensis of T2D.

2.
Cells ; 10(12)2021 11 25.
Artículo en Inglés | MEDLINE | ID: mdl-34943813

RESUMEN

Acute respiratory distress syndrome (ARDS) is a serious lung condition characterized by severe hypoxemia leading to limitations of oxygen needed for lung function. In this study, we investigated the effect of anandamide (AEA), an endogenous cannabinoid, on Staphylococcal enterotoxin B (SEB)-mediated ARDS in female mice. Single-cell RNA sequencing data showed that the lung epithelial cells from AEA-treated mice showed increased levels of antimicrobial peptides (AMPs) and tight junction proteins. MiSeq sequencing data on 16S RNA and LEfSe analysis demonstrated that SEB caused significant alterations in the microbiota, with increases in pathogenic bacteria in both the lungs and the gut, while treatment with AEA reversed this effect and induced beneficial bacteria. AEA treatment suppressed inflammation both in the lungs as well as gut-associated mesenteric lymph nodes (MLNs). AEA triggered several bacterial species that produced increased levels of short-chain fatty acids (SCFAs), including butyrate. Furthermore, administration of butyrate alone could attenuate SEB-mediated ARDS. Taken together, our data indicate that AEA treatment attenuates SEB-mediated ARDS by suppressing inflammation and preventing dysbiosis, both in the lungs and the gut, through the induction of AMPs, tight junction proteins, and SCFAs that stabilize the gut-lung microbial axis driving immune homeostasis.


Asunto(s)
Ácidos Araquidónicos/uso terapéutico , Endocannabinoides/uso terapéutico , Microbioma Gastrointestinal , Tracto Gastrointestinal/patología , Pulmón/patología , Alcamidas Poliinsaturadas/uso terapéutico , Síndrome de Dificultad Respiratoria/tratamiento farmacológico , Síndrome de Dificultad Respiratoria/microbiología , Animales , Péptidos Antimicrobianos/metabolismo , Ácidos Araquidónicos/farmacología , Butiratos/metabolismo , Ciego/patología , Separación Celular , Colon/efectos de los fármacos , Colon/patología , Análisis Discriminante , Disbiosis/complicaciones , Disbiosis/microbiología , Endocannabinoides/farmacología , Enterotoxinas , Femenino , Tracto Gastrointestinal/efectos de los fármacos , Ganglios Linfáticos/efectos de los fármacos , Ganglios Linfáticos/patología , Activación de Linfocitos/efectos de los fármacos , Ratones Endogámicos C57BL , Neumonía/tratamiento farmacológico , Neumonía/microbiología , Alcamidas Poliinsaturadas/farmacología , Síndrome de Dificultad Respiratoria/complicaciones , Linfocitos T/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA